Hurry up and wait? Accelerating access to the three I's for HIV-TB

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 7, 2012, Pages 853-854

  Granich, Reuben ^a   Getahun, Haileyesus ^a   Hirnschall, Gottfried ^a   Raviglione, Mario C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL TRANSMISSION; CD4 LYMPHOCYTE COUNT; DRUG COST; DRUG EFFICACY; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS CONTROL; VIRUS TRANSMISSION;

ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; INFECTION CONTROL; ISONIAZID; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84862232772     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0406     Document Type: Editorial

References (19)

1. Boyles T H, Maartens G. Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults? Int J Tuberc Lung Dis 2012; 16: 857-859.
2. Fenner L, Rieder H L. Isoniazid preventive therapy for all: are we ready? Int J Tuberc Lung Dis 2011; 15: 1281-1282.
3. Dye C. Practical preventive therapy for tuberculosis? [Editorial] N Engl J Med. 2011; 365: 2230-2231.
4. World Health Organization. WHO Three I's meeting: intensifi ed case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Report of a joint WHO HIV/AIDS and TB Department meeting, 2-4 April, 2008, Geneva, Switzerland: WHO, 2008. http://www.who.int/ hiv/pub/meetingreports/WHO-3Is-meeting-report.pdf Accessed May 2012.
5. World Health Organization. WHO policy on collaborative TB/ HIV activities: guidelines for national programmes and other stakeholders. WHO/HTM/TB/2012.1. WHO/HIV/2012.1. Geneva, Switzerland: WHO, 2012. http://whqlibdoc.who.int/ publications/2012/9789241503006-eng.pdf Accessed May 2012.
6. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO/HTM/TB/2009.419. Geneva, Switzerland: WHO, 2009. http://whqlibdoc.who.int/publications/2009/ 9789241598323-eng.pdf Accessed May 2012.
7. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. WHO guidelines 2011. Geneva, Switzerland: WHO, 2011. http://www.who. int/ hiv/pub/tb/9789241500708/en/index.html Accessed May 2012.
8. Getahun H, Kittikraisak W, Heilig C M, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8(1): e1000391.
9. World Health Organization, UNAIDS, UNICEF. Global HIV/ AIDS response: epidemic update and health sector progress towards universal access. Progress report 2011. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/ publications/2011/ 9789241502986-eng.pdf Accessed May 2012.
10. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011 http://www.who.int/tb/ publications/global-report/2011/gtbr11-full.pdf Accessed May 2012.
11. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010(1): CD000171.
12. Samandari T, Agizew T B, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, doubleblind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
13. Charalambous S, Grant A D, Innes C, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010; 24 (Suppl 5): S5-S13.
14. Churchyard G, Fielding K, Lewis J, et al., on behalf of the Thibela TB Team. Community-wide isoniazid preventive therapy does not improve TB control among gold miners: the Thibela TB Study, South Africa. Seattle, WA, USA: 19th Conference on Retroviruses and Opportunistic Infections, March 2012, Session 41 [Abstract #150aLB].
15. Fielding K, Grant A, Lewis J, Hayes R, Churchyard G. Individual-level effect of isoniazid preventive therapy on risk of TB: the Thibela TB study. Seattle, WA, USA: 19th Conference on Retroviruses and Opportunistic Infections, March 2012, Session 41 [Abstract #150bLB].
16. Durovni B, Saraceni V, Pacheco A, et al. Impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death in TB/HIV in the Rio de Janeiro (THRio) study. International AIDS Society. Rome, Italy: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 2011 [WELBB18].
17. World Health Organization. More than 900 000 lives saved by protecting people living with HIV from TB [Note for the media]. Geneva, Switzerland: WHO, 2 March 2012. http:// www.who.int/mediacentre/news/notes/2012/tb-hiv-guide- 20120302/en/index.html Accessed May 2012.
18. Suthar A B, Lawn S D, del Amo J, et al. Antiretroviral therapy for prevention of HIV-associated tuberculosis in developing countries: a systematic review and meta-analysis. PLoS Med 2012 [in press].
19. Samandari T, Agizew T, Nyirenda S, et al. TB incidence increase after cessation of 36 months isoniazid prophylaxis in HIV+ adults in Botswana. Seattle, WA, USA: 19th Conference on Retroviruses and Opportunistic Infections. March 2012 [Abstract #147].